Table 3.

Relationship Between sCCL22 and Survival, Cox Regressions Stratified by Histology, UCSF Adult Glioma Study, 1997–2012

Variable	Category	All Cases
		#	# Deceased	MS**	Hazard Ratio*	P-Value
Log CCL22	NA	1208	798	873	0.81 (0.72–0.91)	0.0003
sCCL22 value (ng/mL)***	0.03–1.05 (Q1)	607	448	611	Referent	NA
	1.05–15.13 (Q2 – Q4)	601	350	1446	0.80 (0.69–0.93)	0.003
Variable	Category	GBM Cases
		#	# Deceased	MS**	Hazard Ratio*	P-Value
Log CCL22	NA	681	614	520	0.79 (0.69–0.91)	0.001
sCCL22 value (ng/mL)***	0.03–1.05 (Q1)	404	370	479	Referent	NA
	1.05–15.13 (Q2 – Q4)	277	244	598	0.85 (0.72–1.01)	0.06
Variable	Category	Non-GBM Cases
		#	# Deceased	75% survival**	Hazard Ratio*	P-Value
Log CCL22	NA	527	184	1380	0.90 (0.70–1.15)	0.41
sCCL22 value (ng/mL)***	0.03–1.05 (Q1)	203	78	948	Referent	NA
	1.05–15.13 (Q2 – Q4)	324	106	1687	0.84 (0.61–1.15)	0.28

^*The following variables were controlled for in the models: age, gender, race (white/non-white), 1st course of treatment (radiation, surgery, temodar, other chemo), dexamethasone use at blood draw, smoking (ever/never), college degree (yes/no), blooddays (days between dx and blood draw).

^**MS=Median survival days. For non-GBM cases, median survival was not available due to high % censored observations so the cutoff where 75% of the cases were still alive was used instead of the median.

^***Quartiles were based on only sCCL22 values in controls.

Note: We did not include IDH status in the final survival models since it was not available for 378 cases. However, when we included IDH in the models we found similar results (Log CCL22 HR and 95% CI for all cases=0.88 (0.76–1.03), GBM cases=0.81 (0.68–0.95), and Non-GBM cases=1.11 (0.77–1.60)). We also did not include 1p/19q co-deletion status as we only had this on 112 of the 165 oligodendroglial cases. However, we ran the survival models for the 112 cases with and without 1p/19q in the model and found similar results (Without 1p/19q: HR=0.40 (0.13–1.26), With 1p/19q: HR=0.47 (0.15–1.46)).